Report: EU seeking new contract with Pfizer-BioNTech for additional vaccines
Unnamed EU official says up to 1.8 billion doses could be delivered in 2022 and 2023
The European Commission (the EU’s executive commission) is looking for EU governments’ approval to launch talks with Pfizer and BioNTech for the purchase of up to 1.8 billion doses of their Covid-19 vaccines to be delivered in 2022 and 2023, an EU official told Reuters.
The EU official asked not to be named because the matter is still confidential but said that the EU executive had already decided to approach Pfizer-BioNTech, and that EU governments backed the plan, though there was not yet a definitive approval.
A commission spokesperson confirmed to Reuters of plans to buy the additional doses, half of which would be optional. The person also confirmed that the EU executive had already identified one supplier, a manufacturer of mRNA vaccines, but did not provide any further details beyond that.
An Exploration of Compounding Practices
May 22nd 2025In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.
